Hologic, Inc.
- Jurisdiction
United States - LEI
549300DYP6F5ZJL0LB74 - ISIN
US4364401012 (HOLX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€59.45 3.4% undervalued - Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. Read full profile
Stock price
Fundamentals
- Net revenue
€3.44B - Gross margin
51.8% - EBIT
€603.46M - EBIT margin
17.5% - Net income
€475.18M - Net margin
13.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | April 7, 2025 | $1.00K–$15.00K |
Earnings Calls
Latest earnings call: May 2, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
| Ray Dalio |
|
|
|
Sell |